Product image of Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert Set

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed to stimulate ovarian follicular development and ovulation in women with infertility related to anovulation or hypogonadotropic hypogonadism.

GNH India supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Set, a gonadotropin used in reproductive medicine, addresses several infertility‑related conditions.

  • Infertility due to anovulation: promotes follicular growth and induces ovulation.
  • Controlled ovarian stimulation for assisted reproductive technologies: enhances the number of mature oocytes retrieved.
  • Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal ovarian function.

How It Works

  • Follicle‑Stimulating Hormone and Luteinising Hormone in Meriofert Set bind to their respective receptors on ovarian granulosa and theca cells. Activation of FSH receptors stimulates follicular maturation and estradiol synthesis, while LH receptor activation supports luteinisation and final oocyte maturation, collectively facilitating ovulation.

Side Effects

Adverse reactions may occur with any gonadotropin therapy. Monitoring and prompt reporting are essential.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the injection site.
  • Abdominal discomfort: transient bloating or mild cramping.
  • Headache: mild to moderate intensity.
  • Nausea: occasional upset stomach.
  • Breast tenderness: mild swelling or soreness.
  • Mild ovarian hyperstimulation: limited follicular response.

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, or respiratory distress.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Allergic reactions: rash, itching, or anaphylaxis.
  • Multiple pregnancy: twins or higher order gestations.
  • Ectopic pregnancy: implantation outside the uterine cavity.
  • Severe abdominal pain: possible ovarian torsion or rupture.

Precautions & Warnings

Use Meriofert Set under specialist supervision with appropriate monitoring.

  • Assess baseline ovarian reserve: perform ultrasound and hormone profiling before initiation.
  • Monitor estradiol levels: adjust dosage to avoid excessive stimulation.
  • Evaluate for contraindications: avoid in active malignancy or uncontrolled thyroid disease.
  • Counsel on signs of OHSS: educate patients to seek immediate care if symptoms arise.
  • Review concomitant medications: consider interactions that may amplify ovarian response.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions can modify the efficacy or safety of Meriofert Set.

Major Interactions (Avoid)

  • Concurrent use of other gonadotropins: may markedly increase risk of ovarian hyperstimulation syndrome.
  • High‑dose estrogen therapy: can blunt the intended ovarian response.

Moderate Interactions (Monitor Closely)

  • GnRH antagonists or agonists: may require dosage adjustments.
  • Anticoagulants: monitor for bleeding if invasive procedures are planned.
  • Thyroid hormone replacement: ensure euthyroid status to optimise response.
  • Corticosteroids: may affect follicular development, requiring close observation.

Frequently Asked Questions

Meriofert Set contains follicle‑stimulating hormone and luteinising hormone and is used to treat infertility caused by anovulation, to support controlled ovarian stimulation in assisted reproductive technologies, and to replace deficient gonadotropins in women with hypogonadotropic hypogonadism.

The hormones bind to FSH and LH receptors on ovarian cells. FSH promotes follicle growth and estradiol production, while LH supports luteinisation and final oocyte maturation, together facilitating ovulation and improving the chances of conception.

The dose of Meriofert Set is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian reserve, treatment protocol and response to therapy.

Meriofert Set is intended for use before conception to induce ovulation. Its safety in established pregnancy or while breastfeeding has not been established, and it should only be used under medical supervision in the pre‑conception phase.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Meriofert Set combines both FSH and LH activity in a single formulation, whereas some alternatives provide only FSH or require separate LH supplementation. This dual action can simplify dosing schedules but the choice depends on individual patient characteristics and clinician preference.

Meriofert Set should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The product is supplied as a sterile injectable solution and is administered by a trained healthcare professional via intramuscular or subcutaneous injection, following the dosing schedule prescribed by the treating physician.

The most serious risks include severe ovarian hyperstimulation syndrome, thromboembolic events, allergic reactions such as anaphylaxis, and the possibility of multiple or ectopic pregnancies. Prompt medical attention is required if any of these occur.

Meriofert Set is contraindicated in women with active ovarian or breast cancer, uncontrolled thyroid disease, severe ovarian cysts, or known hypersensitivity to any component of the formulation. It should also be avoided in patients with a history of severe ovarian hyperstimulation syndrome.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT